Literature DB >> 12172092

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients.

Li Xu1, Stéphane Hué, Stephen Taylor, Daina Ratcliffe, Judith A Workman, Susan Jackson, Patricia A Cane, Deenan Pillay.   

Abstract

In-vitro differences in T-20 susceptibility among HIV-1 subtypes have been reported. We therefore studied the T-20 binding domain of a variety of virus subtypes from both antiretroviral-naive and -experienced patients. Minimal variation in the HR-1 region of gp41 was observed, especially within the region responsible for T-20 resistance. Any subtype differences in T-20 susceptibility do not appear to be related to HR-1 genetic variation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172092     DOI: 10.1097/00002030-200208160-00016

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

Review 1.  Enfuvirtide.

Authors:  Toni M Dando; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.

Authors:  Yun Zhu; Lu Lu; Liling Xu; Hengwen Yang; Shibo Jiang; Ying-Hua Chen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Authors:  L Xu; A Pozniak; A Wildfire; S A Stanfield-Oakley; S M Mosier; D Ratcliffe; J Workman; A Joall; R Myers; E Smit; P A Cane; M L Greenberg; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Authors:  Emmanuel Desmezieres; Nidhi Gupta; Russell Vassell; Yong He; Keith Peden; Lev Sirota; Zhongning Yang; Paul Wingfield; Carol D Weiss
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 6.  Enfuvirtide: a review of its use in the management of HIV infection.

Authors:  Vicki Oldfield; Gillian M Keating; Greg Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Authors:  Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M Lange; Min Lu; Ben Berkhout
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

9.  Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.

Authors:  Marintha L Heil; Julie M Decker; Jeffrey N Sfakianos; George M Shaw; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.